<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty-nine adult patients with high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> that progressed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were registered for the multicenter study of the Japan Adult <z:hpo ids='HP_0001909'>Leukemia</z:hpo> Study Group </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-three patients were evaluable for the analysis </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="42068">Idarubicin</z:chebi> 12 mg/m2 per day for 3 days and continuous <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> 100 mg/m2 per day for 7 days were given as induction therapy, followed by postremission chemotherapy after complete remission (CR) </plain></SENT>
<SENT sid="3" pm="."><plain>Because elderly patients and those with <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypoplastic marrow</z:e> usually have complications after intensive chemotherapy, often causing early <z:hpo ids='HP_0011420'>death</z:hpo>, the treatment dose was reduced to 60% or 80% according to the presence of 3 risk factors: age 60 years or older, performance status 2 or more, or presence of <z:hpo ids='HP_0005528'>hypoplastic bone marrow</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Of the 43 evaluable patients (median age, 58 years), 26 (60%) achieved CR </plain></SENT>
<SENT sid="5" pm="."><plain>Two patients (5%) died within 2 months of completion of induction therapy </plain></SENT>
<SENT sid="6" pm="."><plain>The CR rates for patients treated with 100%, 80%, and 60% of the chemotherapy dose were 55% (12 of 22), 63% (10 of 16), and 80% (4 of 5), respectively, indicating that the risk factor-adjusted dose attenuation was appropriately applied to those who might have had problems with the original dose, thus reducing regimen-related mortality rate </plain></SENT>
<SENT sid="7" pm="."><plain>The median overall survival of the 43 patients was 8 months </plain></SENT>
</text></document>